title: Dosing of cancer patients with low or absent renal function.
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne and Derby Hospitals NHS Trust, Derby, UK. alan.boddy@ncl.ac.uk
authors.forename: Alan
authors.initials: A
authors.lastname: Boddy
authors.forename: Melanie
authors.initials: M
authors.lastname: Griffin
authors.forename: Sarah
authors.initials: S
authors.lastname: Knowles
authors.forename: Mojca
authors.initials: M
authors.lastname: Persic
authors.forename: Ian
authors.initials: I
authors.lastname: Scott
authors.forename: Julie
authors.initials: J
authors.lastname: Errington
authors.forename: Gareth
authors.initials: G
authors.lastname: Veal
mesh_terms: D019540:Area Under Curve; D016190:Carboplatin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy*; D051437:Renal Insufficiency / Q000150:complications*
chemical_list: D005047:Etoposide; D016190:Carboplatin